Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity

被引:0
|
作者
Ng, Ho Yu [1 ]
Liao, Yunshi [2 ]
Cheung, Ching Lung [3 ,4 ]
Zhang, Ruiqi [5 ]
Chan, Kwok Hung [6 ]
Seto, Wai-Kay [5 ]
Leung, Wai K. [5 ]
Hung, Ivan F. N. [5 ]
Lam, Tommy T. Y. [2 ,4 ,7 ]
Cheung, Ka Shing [5 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Sch Publ Hlth, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
[4] Lab Data Discovery Hlth Ltd, 19W Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China
[5] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Med, Hong Kong, Peoples R China
[6] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Microbiol, Hong Kong, Peoples R China
[7] Ctr Immunol & Infect Ltd, 17W Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
gut microbiota; vaccine; COVID-19; vaccine immunogenicity; BNT162b2 (Pfizer-BioNTech); B-CELL MEMORY; COVID-19; VACCINE; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; AMINO-ACIDS; CYSTEINE; GLUTATHIONE; METABOLITES; MODULATION; HEALTH;
D O I
10.3389/fimmu.2025.1534787
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction BNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity.Methods This cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at baseline and day 180 after first dose, and tested for neutralizing antibodies (NAb) against receptor-binding domain (RBD) of wild type SARS-CoV-2 virus using chemiluminescence immunoassay. Shotgun DNA metagenomic sequencing was performed to characterize baseline stool microbiome. Baseline metabolites were measured by gas and liquid chromatography-tandem mass spectrometry (GC-MS/MS and LC-MS/MS). Primary outcome was persistent high NAb response (defined as top 25% of NAb level) at day 180. Putative bacterial species and metabolic pathways were identified using linear discriminant analysis [LDA] effect size analysis. Multivariable logistic regression adjusting for clinical factors was used to derive adjusted odds ratio (aOR) of outcome with bacterial species and metabolites.Results Of 242 subjects (median age: 50.2 years [IQR:42.5-55.6]; male:85 [35.1%]), 61 (25.2%) were high-responders while 33 (13.6%) were extreme-high responders (defined as NAb >= 200AU/mL). None had COVID-19 at end of study. Ruminococcus bicirculans (log10LDA score=3.65), Parasutterella excrementihominis (score=2.82) and Streptococcus salivarius (score=2.31) were enriched in high-responders, while Bacteroides thetaiotaomicron was enriched in low-responders (score=-3.70). On multivariable analysis, bacterial species (R. bicirculans-aOR: 1.87, 95% CI: 1.02-3.51; P. excrementihominis-aOR: 2.2, 95% CI: 1.18-4.18; S. salivarius-aOR: 2.09, 95% CI: 1.13-3.94) but not clinical factors associated with high response. R. bicirculans positively correlated with most metabolic pathways enriched in high-responders, including superpathway of L-cysteine biosynthesis (score=2.25) and L-isoleucine biosynthesis I pathway (score=2.16) known to benefit immune system. Baseline serum butyrate (aOR:10.00, 95% CI:1.81-107.2) and isoleucine (aOR:1.17, 95% CI:1.04-1.35) significantly associated with extreme-high vaccine response.Conclusion Certain gut bacterial species, metabolic pathways and metabolites associate with longer-term COVID-19 vaccine immunogenicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Baseline Gut Microbiota Was Associated with Long-Term Immune Response at One Year Following Three Doses of BNT162b2
    Zhang, Li-Na
    Tan, Jing-Tong
    Ng, Ho-Yu
    Liao, Yun-Shi
    Zhang, Rui-Qi
    Chan, Kwok-Hung
    Hung, Ivan Fan-Ngai
    Lam, Tommy Tsan-Yuk
    Cheung, Ka-Shing
    VACCINES, 2024, 12 (08)
  • [22] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers
    Rojkovich, Bernadette
    Nemeth, Dora
    Torok, Eszter
    Szabo, Bernadette
    Pinter, Agnes
    Juhasz, Istvan
    Weidl, Marton
    Lanyi, Eva
    Pavel-Szecsko, Judit
    Lazar, Imre
    Perduk, Andras
    Reiter, Jozsef
    Nagy, Gyorgy
    Nagy, Erzsebet
    Geher, Pal
    ORVOSI HETILAP, 2021, 162 (39) : 1551 - 1557
  • [23] Correspondence on 'BNT162b2 vaccine-associated myo/pericarditis in adolescents'
    Sookaromdee, Pathum
    Wiwanitkit, Viroj
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52 (08)
  • [24] Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
    Ligumsky, Hagai
    Dor, Herut
    Etan, Tal
    Golomb, Inbal
    Nikolaevski-Berlin, Alla
    Greenberg, Inbal
    Halperin, Tamar
    Angel, Yoel
    Henig, Oryan
    Spitzer, Avishay
    Slobodkin, Marina
    Wolf, Ido
    LANCET ONCOLOGY, 2022, 23 (02): : 193 - 195
  • [25] Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
    Peled, Yael
    Ram, Eilon
    Lavee, Jacob
    Segev, Amit
    Matezki, Shlomi
    Wieder-Finesod, Anat
    Halperin, Rebecca
    Mandelboim, Michal
    Indenbaum, Victoria
    Levy, Itzchak
    Sternik, Leonid
    Raanani, Ehud
    Afek, Arnon
    Kreiss, Yitshak
    Lustig, Yaniv
    Rahav, Galia
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (02): : 148 - 157
  • [26] Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study
    Itzhaki Ben Zadok, Osnat
    Shaul, Aviv A.
    Ben-Avraham, Binyamin
    Yaari, Vicky
    Ben Zvi, Haim
    Shostak, Yael
    Pertzov, Barak
    Eliakim-Raz, Noa
    Abed, Galia
    Abuhazira, Miriam
    Barac, Yaron D.
    Mats, Israel
    Kramer, Mordechai R.
    Aravot, Dan
    Kornowski, Ran
    Ben-Gal, Tuvia
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (09) : 1555 - 1559
  • [27] Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients
    Marinaki, Smaragdi
    Adamopoulos, Stamatis
    Degiannis, Dimitrios
    Roussos, Sotirios
    Pavlopoulou, Ioanna D.
    Hatzakis, Angelos
    Boletis, Ioannis N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (08) : 2913 - 2915
  • [28] Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
    Psichogiou, Mina
    Karabinis, Andreas
    Poulakou, Garyphallia
    Antoniadou, Anastasia
    Kotanidou, Anastasia
    Degiannis, Dimitrios
    Pavlopoulou, Ioanna D.
    Chaidaroglou, Antigoni
    Roussos, Sotirios
    Mastrogianni, Elpida
    Eliadi, Irene
    Basoulis, Dimitrios
    Petsios, Konstantinos
    Leontis, Konstantinos
    Kakalou, Eleni
    Protopapas, Konstantinos
    Jahaj, Edison
    Pratikaki, Maria
    Syrigos, Konstantinos N.
    Lagiou, Pagona
    Gogas, Helen
    Tsiodras, Sotirios
    Magiorkinis, Gkikas
    Paraskevis, Dimitrios
    Sypsa, Vana
    Hatzakis, Angelos
    VACCINES, 2021, 9 (09)
  • [29] Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
    Naruse, Hiroyuki
    Ito, Hiroyasu
    Izawa, Hideo
    Sarai, Masayoshi
    Ishii, Junnichi
    Sakaguchi, Eirin
    Murakami, Reiko
    Ando, Tatsuya
    Fujigaki, Hidetsugu
    Saito, Kuniaki
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [30] BNT162b2 Covid-19 Vaccine in Adolescents
    Lin, Chen-Hsing
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (14): : 1342 - 1343